ViiV Steals A March On Gilead with HIV Doublet Data

ViiV Healthcare intends to seek regulatory approval for a fixed-dose combination of Tivicay and Epivir later this year based on positive 48-week data from the GEMINI studies in treating HIV that analysts say have helped to lift key uncertainties about the treatment and boost ViiV's competitive position versus key rival Gilead Sciences, which has favored triplet therapy.

3D Illustration of Immune System cells attacking a HIV Virus.
ViiV's GEMINI 1 & 2 studies met their primary endpoint in HIV • Source: Shutterstock

ViiV Healthcare 's two-drug approach to treating HIV received a solid boost from its updated GEMINI 1 and 2 studies which at the 48-week juncture met their primary endpoint and, importantly, yielded data that analysts said should counter fears of lower efficacy in high viral loads and the higher theoretical risk of resistance generation from the duo regimen compared with a three-drug combination. 

The evidence was contained in an update on the ongoing and identical GEMINI 1 and 2 studies which showed the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D